Table 2. Association of BMI and CCB.
| Modela | CCB, HR (95% CI) (N = 86 635)b | |||
|---|---|---|---|---|
| BMI 18.5 to <24 (n = 33 259) | BMI 24 to <28 (n = 37 069) | BMI ≥28 (n = 16 307) | Per 5-unit increase | |
| CCB, No (%) | 438 (1.32) | 546 (1.47) | 274 (1.68) | NA |
| Incidence rate, No./10 000 person-y | 12.38 | 13.90 | 12.89 | NA |
| Model 1 | 1 [Reference] | 1.05 (0.93-1.19) | 1.26 (1.09-1.47) | 1.14 (1.05-1.23) |
| Model 2 | 1 [Reference] | 1.04 (0.91-1.18) | 1.23 (1.05-1.43) | 1.11 (1.02-1.21) |
| Model 3 | 1 [Reference] | 1.03 (0.91-1.17) | 1.22 (1.04-1.42) | 1.11 (1.02-1.21) |
| Model 4 | 1 [Reference] | 1.03 (0.91-1.17) | 1.21 (1.04-1.42) | 1.11 (1.02-1.21) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCB, cardiac conduction block; HR, hazard ratio; NA, not applicable.
Model 1 adjusted for age and sex. Model 2 adjusted for age, sex, smoking, drinking, high salt intake, physical activity, high-sensitivity C-reactive protein level, low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol level, estimated glomerular filtration rate, hypertension, and diabetes. Model 3 adjusted for all variables in model 2 and myocardial infarction during follow-up and heart failure during follow-up. Model 4 adjusted for all variables in model 3 and antidiabetic treatment, antihypertensive treatment, and lipid-lowering drug use.
CCB is defined as the occurrence of any of the following: high-grade atrioventricular block, complete right bundle branch block, complete left bundle branch block, left anterior fascicular block, or left posterior fascicular block.